Outlook Therapeutics Faces Nasdaq Compliance Challenge Amid European Expansion

Outlook Therapeutics reports Q1 loss, navigates FDA setback and Nasdaq warning while advancing LYTENAVA rollout in Europe with new Swiss partnership.

Outlook Therapeutics finds itself navigating a critical period. The company is simultaneously advancing the European commercial rollout of its ophthalmic solution LYTENAVA while contending with a significant threat to its listing on the Nasdaq Capital Market. This dual challenge raises questions about whether its operational progress abroad can offset regulatory setbacks in the United States and mounting pressure from capital markets.

Financial Results and US Regulatory Stalemate

The company's recent financial disclosures underscore its current difficulties. For the first fiscal quarter, Outlook Therapeutics reported a net loss of $23.1 million, or $0.38 per share. This contrasts sharply with the year-ago period, which showed a profit of $17.4 million. On an adjusted basis, the loss stood at $13.5 million. As of December 31, the firm held cash and equivalents totaling $8.7 million.

The regulatory pathway in the U.S. remains obstructed. Following a Complete Response Letter from the Food and Drug Administration (FDA) in late December, the company has requested a Type A meeting with the regulator. The FDA's rejection cited insufficient evidence of effectiveness for its formulation, ONS-5010. Outlook Therapeutics maintains confidence in the validity of its clinical trial data and aims to reach an agreement with the agency on the next steps for the U.S. approval process.

Nasdaq Issues a Minimum Bid Price Warning

Compounding these challenges, Outlook Therapeutics recently received a formal notice from Nasdaq regarding non-compliance with listing rules. The company's share price closed below the mandatory $1.00 threshold for 30 consecutive business days. To regain compliance and avoid delisting, the stock must trade above $1.00 for a minimum of ten consecutive days prior to August 17, 2026.

Management is evaluating several strategic options to prevent removal from the Nasdaq Capital Market, with a potential reverse stock split being one considered measure. A delisting event would likely severely impact the stock's liquidity and complicate future efforts to raise capital.

European Strategy Advances with Swiss Partnership

Despite these headwinds, the company's European strategy is gaining momentum. Last Thursday, Outlook Therapeutics announced an exclusive distribution agreement with Mediconsult AG for the Swiss market. Under this pact, Mediconsult will manage the marketing, import, distribution, and regulatory coordination with Swissmedic for LYTENAVA.

Market entry in Switzerland is targeted for 2027. This move follows the product's launch in Austria this past January. LYTENAVA is already approved in the European Union and United Kingdom for treating wet age-related macular degeneration (wet AMD). The company reported that European sales doubled in the quarter ending December 31 compared to the preceding three-month period. Further launches in Ireland and the Netherlands are planned before the end of this year.

For the Swiss authorization activities, Mediconsult assumes full responsibility, while Outlook Therapeutics retains control over product manufacturing and intellectual property rights.